Long COVID Syndrome Presenting as Neuropsychiatric Exacerbations in Autism Spectrum Disorder: Insights for Treatment.

Harumi Jyonouchi, Lee Geng, Daniel A Rossignol, Richard E Frye
Author Information
  1. Harumi Jyonouchi: Saint Peter's University Hospital (SPUH), New Brunswick, NJ 08901, USA.
  2. Lee Geng: Saint Peter's University Hospital (SPUH), New Brunswick, NJ 08901, USA.
  3. Daniel A Rossignol: Rossignol Medical Center, Aliso Viejo, CA 92656, USA.
  4. Richard E Frye: Rossignol Medical Center, Phoenix, AZ 85050, USA. ORCID

Abstract

COVID-19 causes not only severe respiratory symptoms, but also long-term sequelae, even if the acute-phase symptoms are minor. Neurological and neuropsychiatric symptoms are emerging as major long-term sequalae. In patients with pre-existing behavioral symptoms, such as individuals with autism spectrum disorders (ASD), the emergence of neuropsychiatric symptoms due to long COVID can be difficult to diagnose and manage. Herein, we present three ASD cases who presented with markedly worsening neuropsychiatric symptoms following COVID-19 exposure and subsequent difficulty in managing the post-COVID neuropsychiatric symptoms. Case 1 contracted SARS-CoV-2 during the early stages of the pandemic and treatment targeting COVID-19-induced immune activation was delayed. Case 2 was asymptomatic in the acute stage of a confirmed COVID-19 exposure, but still developed significant neuropsychiatric symptoms. Case 3 demonstrated a difficult course, partly due to pre-existing immune dysregulation and prior use of multiple immunomodulating agents. In cases 1 and 3 for whom serial blood samples were obtained, notable changes in the production of inflammatory and counter-regulatory cytokines by peripheral blood monocytes were observed. The presented cases illustrate the profound effects of COVID-19 on neuropsychiatric symptoms in ASD subjects and the difficulty of managing long-COVID symptoms.

Keywords

References

  1. J Clin Med. 2022 May 06;11(9): [PMID: 35566737]
  2. J Neurol Sci. 2022 Mar 15;434:120162 [PMID: 35121209]
  3. Neurol Sci. 2013 Jun;34(6):1003-4 [PMID: 22797722]
  4. Immunol Invest. 2021 Nov;50(8):884-890 [PMID: 32633162]
  5. Trends Neurosci. 2021 Jun;44(6):441-451 [PMID: 33674135]
  6. Nature. 2022 Jun;606(7914):585-593 [PMID: 35483404]
  7. JAMA Netw Open. 2021 May 3;4(5):e2111417 [PMID: 34037731]
  8. Curr Opin Oncol. 2019 Nov;31(6):531-539 [PMID: 31449084]
  9. Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487 [PMID: 34870392]
  10. Microb Biotechnol. 2022 Apr;15(4):1035-1049 [PMID: 35182108]
  11. J Autism Dev Disord. 2021 Dec;51(12):4253-4270 [PMID: 33624215]
  12. BMC Med. 2022 Jan 14;20(1):26 [PMID: 35027067]
  13. Cell. 2022 Jul 7;185(14):2452-2468.e16 [PMID: 35768006]
  14. Acta Paediatr. 2021 Mar;110(3):914-921 [PMID: 33205450]
  15. Inflamm Res. 2022 Mar;71(3):293-307 [PMID: 35113170]
  16. Int J Mol Sci. 2019 Sep 24;20(19): [PMID: 31554204]
  17. Lancet Infect Dis. 2022 Apr;22(4):e102-e107 [PMID: 34951953]
  18. Front Neurol. 2021 Feb 12;12:639319 [PMID: 33643212]
  19. Brain Sci. 2020 Sep 11;10(9): [PMID: 32932826]
  20. Curr Psychol. 2022 Oct 19;:1-12 [PMID: 36277263]
  21. Front Cell Dev Biol. 2022 May 12;10:852752 [PMID: 35646933]
  22. Pediatr Infect Dis J. 2022 Apr 1;41(4):e139-e141 [PMID: 35121715]
  23. Nat Immunol. 2022 Feb;23(2):194-202 [PMID: 35105985]
  24. Brain Behav Immun. 2022 Mar;101:93-135 [PMID: 34973396]
  25. Medicina (Kaunas). 2021 Apr 26;57(5): [PMID: 33925784]
  26. Int J Environ Res Public Health. 2022 Sep 20;19(19): [PMID: 36231151]
  27. J Policy Pract Intellect Disabil. 2022 Mar;19(1):35-47 [PMID: 35601014]
  28. Front Immunol. 2022 May 12;13:830990 [PMID: 35634324]
  29. Front Pharmacol. 2022 Apr 04;13:806568 [PMID: 35444538]
  30. Cell. 2019 Jan 10;176(1-2):43-55.e13 [PMID: 30528430]

Grants

  1. None/Jonty Foundation, St. Paul, MN
  2. None/The Brain Foundation, Pleasanton, CA.

Word Cloud

Created with Highcharts 10.0.0symptomsneuropsychiatricCOVID-19ASDcasesCaselong-termpre-existingdueCOVIDdifficultpresentedexposuredifficultymanaging1SARS-CoV-2immune3bloodcausessevererespiratoryalsosequelaeevenacute-phaseminorNeurologicalemergingmajorsequalaepatientsbehavioralindividualsautismspectrumdisordersemergencelongcandiagnosemanageHereinpresentthreemarkedlyworseningfollowingsubsequentpost-COVIDcontractedearlystagespandemictreatmenttargetingCOVID-19-inducedactivationdelayed2asymptomaticacutestageconfirmedstilldevelopedsignificantdemonstratedcoursepartlydysregulationpriorusemultipleimmunomodulatingagentsserialsamplesobtainednotablechangesproductioninflammatorycounter-regulatorycytokinesperipheralmonocytesobservedillustrateprofoundeffectssubjectslong-COVIDLongSyndromePresentingNeuropsychiatricExacerbationsAutismSpectrumDisorder:InsightsTreatmentmonocytecytokine

Similar Articles

Cited By